$0.83
+0.00 (+0.18%)
Open$0.84
Previous Close$0.83
Day High$0.86
Day Low$0.80
52W High$34.80
52W Low$0.86
Volume—
Avg Volume167.0K
Market Cap1.88M
P/E Ratio—
EPS$-14.33
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+462.9% upside
Current
$0.83
$0.83
Target
$4.68
$4.68
$2.81
$4.68 avg
$5.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 31.64M | 32.42M | 3.13M |
| Net Income | -25,402,811 | -23,427,123 | -134,676 |
| Profit Margin | -80.3% | -76.3% | -4.3% |
| EBITDA | -18,574,729 | -18,081,763 | -218,349 |
| Free Cash Flow | — | — | -122,296 |
| Rev Growth | -2.4% | -2.4% | +0.4% |
| Debt/Equity | — | — | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |